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The recognition that interferons (IFN)1 markedly affect a wide variety of immune 
responses  has  led  to  speculation  that  they  may  be  involved  in  development  of 
autoimmune diseases. Many patients with systemic lupus erythematosus (SLE) have 
high levels of circulating IFN (1-4). Since the IFN was inactivated at pH  2, it was 
originally  assumed  to  be  "immune"  or  gamma  IFN  (1).  However,  we  recently 
demonstrated that the IFN in patients with SLE is not gamma IFN, but rather is an 
unusual acid-labile form of human leukocyte, or alpha, IFN (2, 3). A similar IFN was 
also found in patients with rheumatoid arthritis  (3), autoimmune vasculitis (4), and 
the acquired immunodeficiency syndrome (5).  In contrast, no IFN was detected in 
patients  with  drug-induced  lupus  (3),  suggesting  that  production of IFN  may be 
related to idiopathic immune disorders. 
Others found that SLE lymphocytes were poor producers of IFN in culture (6), but 
they neither characterized the IFN made in vitro nor measured serum IFN levels in 
their patients. We therefore re-evaluated IFN production by lymphocytes from SLE 
patients  with and  without endogenous IFN.  We also quantitated  the IFN-induced 
enzyme 2'-5'-oligoadenylate (2-5A) synthetase in cells from SLE patients. This enzyme 
is induced in cultured cells treated with IFN  (7)  and in lymphocytes from patients 
undergoing IFN therapy (8) or viral infections (9).  The results suggest that  most, if 
not all, SLE patients produce IFN that has biological significance, as demonstrated 
by elevated 2-5A synthetase in circulating lymphocytes. 
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Materials  and  Methods 
Sera and Patient Specimens.  Serum  and  heparinized  blood  were  obtained  with  informed 
consent  from patients with SLE attending the Clinical Center at  the National Institutes of 
Health for regularly scheduled appointments. 
IFNAssay.  IFN was quantitated using a semi-micromethod on human fibroblasts (GM2504) 
trisomic for chromosome 21,  as described previously (2,  3,  5).  Results were standardized to 
National Institutes of Health no. 023-901-527 reference human alpha IFN. 
Characterization of IFN.  Preliminary identification of alpha IFNs was  made  by  assaying 
samples on bovine (MDBK) cells, as described previously (2, 3, 5). Human alpha IFN has full 
antiviral activity on MDBK cells, whereas human beta and gamma IFNs are inactive on these 
cells. These results were confirmed using highly specific rabbit anti-IFN antibodies (2, 3, 5). 
To determine the stability of an IFN at pH 2,  100-#1 aliquots were adjusted to pH 2 with 1 
N  HC1  (6-10 /~1 per sample)  as previously described (2,  3,  5);  controls received equivalent 
volumes of sterile distilled H20. Reference human alpha, beta, and gamma IFNs diluted to 100 
IU/ml in normal human serum (Flow Laboratories, McLean, VA) were treated in an identical 
manner.  Residual IFN was assayed on GM2504 cells as described above.  Reference human 
alpha and beta IFNs were completely stable during this procedure, whereas human  gamma 
IFN was inactivated >30-fold (2, 3, 5). Control experiments with both mouse and human IFNs 
have shown that this method gives results equivalent to dialysis against buffer at pH 2, and is 
more convenient with small samples. 
Induction of IFN In Vitro.  Mononuclear cells were isolated from heparinized peripheral blood 
on Ficoll-hypaque (LSM Solution, Litton Bionetics, Kensington, MD) gradients, resuspended 
to  1-2  ×  106 cells/ml in RPMI  1640  medium supplemented with 2-5%  normal human  AB 
serum (Flow Labs), and distributed in 0.2-ml aliquots to wells of microtiter plates. IFN inducers 
(UV-inaetivated Newcastle disease virus (UV-NDV), pokeweed mitogen (PWM), and phyto- 
hemagglutinin  (PHA)  (P-L Biochemicals, Inc., Milwaukee, WI), poly rI:poly rC  (poly I:C), 
and  heat-killed Corynebacterium parvum strain CN6134  (Burroughs Wellcome, Greenville, NC) 
were prepared as  10x concentrates, and  20/11  was added to appropriate wells. Control cells 
received 20/~1 of medium. Final concentrations of each inducer were: UV-NDV, 5.0 plaque- 
forming unit equivalents/cell; PWM, 5.0 and 50 #g/ml; PHA, 0.5 and 5.0 #g/ml; poly I:C, 20 
/~g/ml; and C. parvum, 100/~g/ml. Culture supernatants harvested after various times at 37°C 
were clarified by centrifugation and assayed for IFN on GM2504 cells. 
2-5A  Synthetase Assays.  Mononuclear cell extracts were adsorbed to  poly I:C-agarose for 
synthesis of 2-5A as described previously (10). After incubation for 4-6 h, the supernatants were 
treated with bacterial alkaline phosphatase and assayed for 2-5A by a competition immunoen- 
zymometric assay that employed rabbit antibodies to 2-5A and microtiter wells coated with 
conjugates of 2-5A and derivitized Ficoll (Johnston, M. I., P. F. Torrence, J. Imai, and O. T. 
Preble, manuscript in preparation). Characterization of the antibodies will appear elsewhere 
(Johnston, M. I.,J. Imai, K. Lesiak, and P. F. Torrence, manuscript submitted for publication). 
Results were normalized to picomoles of 2-5A synthesized per hour per A~0 unit of protein. 
Results 
Production of IFN by  Lymphocytes from  SLE  Patients.  Mononuclear  cells  from  SLE 
patients  were  cultured  without  IFN  inducers,  or with  classical inducers  of human 
alpha IFN (UV-NDV), beta IFN (poly I:C), or gamma IFN (PHA or PWM). Culture 
fluids were harvested from mitogen-stimulated cells after  1, 3, 5, and  7 d. However, 
since  IFN  levels  from  normal  lymphocytes  and  SLE  lymphocytes  incubated  with 
PWM  were greatest at 3  d, Table I  shows only the data for 3  d. Lymphocytes from 
IFN-positive patients did not spontaneously secrete IFN in vitro at any time. With 
the exception of the 3-d sample for patient no. 8, no SLE lymphocytes produced IFN 
in response to the T  cell mitogen PHA even though microscopic evaluation showed 
that cell proliferation was fair to good in all cultures. PHA did induce IFN in cultures 
of lymphoeytes from  two  normal  individuals (Table I).  In contrast,  PWM  induced 2142  INTERFERON  IN  SYSTEMIC  LUPUS  ERYTHEMATOSUS 
TABLE  I 
Interferon Production by Mitogen-stimulated Lymphocytes In Vitro 
Serum IFN  Mononuclear Cell 
Donor 
IFN (IU/ml) after stimulation with:* 





normal 1  <4  100  400  800  1,600 
normal 2  <4  25  100  800  1,600 
SLE 1  <4  <4  <4  50  50 
SLE 2  <4  <4  <4  13  50 
SLE 3  <4  <4  <4  400  1,600 
SLE 4  <4  <4  <4  50  50 
SLE 5  <4  <4  <4  50  100 
SLE 6  <4  <4  <4  100  100 
SLE 7  <4  <4  <4  400  400 
SLE 8  <4  50  <4  100  200 
* Mononuclcar cells (1-2 X 10  s cells/ml) were incubated without mitogens, with low (0.5 #g/ml) or high (5.0 #g/ml) doses 
of PHA, or with low (5.0/~g/ml) or high (50.0 #g/ml) doses of PWM. Culture fluids harvested after 3 d were clarifed 
and assayed for IFN on human GM25tM cells. 
TABLE  II 
Interferon Production by UV-ND V-stimulated SLE Lymphocytes 
Serum IFN  IFN produced in response to UV-NDV 
Patients  GM2504  ~ 
Inact. at  Inact. at 
IU/ml*  pH 2*  IU/ml* 
BK  pH 2* 
4  25-100  4-8  800-1,600  2-4  0 
5  <4  --  800-1,600  0.5-2.0  0 
* IFN titers (IU/ml) assayed on human GM2504 fibroblasts. 
Fold-reduction  in  titer after incubation  at pH 2. The values  for reference human  alpha,  beta,  and 
gamma IFNs were 0, 0, and >32 respectively (2, 3, 5). The values for serum IFN samples from the IFN 
+  SLE patients were all 4-8. 
g Ratio of IFN titers in duplicate assays on human GM2504 fibrohlasts  and bovine MDBK cells. Ratios 
for reference human alpha, beta, and gamma IFNs were 0.5-2.0, >32, and >32, respectively. 
IFN production by cells from both normal and SLE patients. However,  lower levels 
of IFN were produced by ceils from most SLE patients (50-400 IU/ml)  than by cells 
from control subjects  (1,600 IU/ml).  These results are similar to previously reported 
data (9). Cells from IFN-positive patients tended to produce less IFN than cells from 
IFN-negative patients. The IFN in these cultures at  1, 3, 5, and 7 d was also assayed 
on  MDBK  cells,  and  like  human  gamma  IFN,  was  completely  inactive  on bovine 
cells. Synthesis of gamma IFN was expected under these conditions (11). 
SLE lymphocytes cultured with poly I:C produced very low levels (8-50 IU/ml)  of 
IFN with little activity on MDBK cells  (data not shown). Others found that normal 
lymphocytes produced 10-150 U  of IFN in response to poly I:C (6). Synthesis of beta 
IFN  might  be  expected  in  response  to  poly  I:C  (11).  Lymphocytes  from  all  SLE 
patients, cultured for 24 h with UV-NDV,  produced 800-1,600 IU/ml of alpha IFN 
that had similar  antiviral activity on bovine and human cells  (Table II).  However, 
unlike  the  serum  IFN  in  these  patients,  the  alpha  IFN  produced  in  vitro  was 
completely stable at pH 2  (Table II), and appears to be like previously studied virus- 
induced alpha IFNs  (11). Neighbor and Grayzell  (6)  found that patients with acute 
SLE did not produce IFN in response to NDV;  none of our patients had acute SLE. 
Normal  human leukocytes stimulated  in vitro with C. paroum-produced IFN  that 
was neutralized by antiserum  to human alpha IFN and active on bovine cells  (12). PREBLE  ET  AL.  2143 
TABLE  III 
Interferon Produttion by SLE Lymphocytes in Response to C. paroum 
IFN produced in response to C. parvum* 
Mononuclear cell  Number of  Serum IFN 
donors  donors  (IU/ml)  IU/ml  _  .  GM2504  Inactivation  Kauo 
(range)  at pH 2 
Normal  6  ~4  1,000--2,000  1-2  4-8 
SLE  5  8-32  100-640  1-2  4-8 
SLE,  6  ___4  500-2,000  1-2  4-8 
* Mononuclear cells were incubated for 24 h  at 37°C with 100 #g/ml of heat-killed C  par0um. Cell culture supcrnatants 
were then assayed for IFN on human GM2504 and bovine MDBK cells, and tested for stability at pH 2 as described in 
Materials and Methods. 
TABLE  IV 
2"5' Oligoadenylate Synthetase in Lymphocytes  fiom SLE Patients 
Mononuclear  Serum IFN  ~  Samples 
2-5A Syntbetase (pmol 2-5A/h/Asm)* 
Normal  Slightly  Very high 
high  (3O4- 
(~200)  (230-250)  1,900) 
IU/ml 
SLE  8-25  9  1  1  7 
SLE  __-4  10  4  1  5 
Normal controls  ----.4  3  3  0  0 
* Cytoplasmic extracts of mononuclear cells  were assayed for 2-5A  synthetase activity as  described  in  Materials and 
Methods. The data presented are the average of at least  two separate determinations for each sample. 
However, the IFN was partially inactivated at pH 2, and therefore appears similar to 
serum IFN in patients with SLE. We confirmed these results using mononuclear cells 
from six normal volunteers (Table III). As in experiments with PWM (Table I), cells 
from IFN-positive SLE patients produced less IFN after stimulation with C. parvum 
than cells from IFN-negative patients or normal subjects  (Table III). However, all 
patients produced IFN with the biological properties expected for C. parvum-induced 
alpha IFN (i.e., active on bovine cells and partially inactivated at pH 2). 
2-5A Synthetase in Serum IFN-Positive and Serum IFN-Negative  Patients with SLE.  IFN 
production by continuous cell lines can often be inhibited by prior exposure to high 
doses of IFN, a  phenomenon known as "blocking." Although purified IFN did not 
have blocking activity on some mouse cell lines (13),  the effects of acid-labile alpha 
IFN, which predominates in patients with SLE, are unknown. Since cells from serum 
IFN-negative  SLE  patients  produced  abnormally  low  levels  of IFN  in  vitro,  we 
investigated the possibility that cells from these patients had also been exposed to 
IFN  in  vivo.  To  do  this,  we  quantitated  2-5A  synthetase  activity in  extracts  of 
mononuclear cells. Since mice infected with virus may have elevated 2-5A synthetase 
before, during, and after the peak of circulating inferferon, Revel and co-workers (14) 
postulated that (a)  cells exposed to IFN may contain synthetase for some time after 
IFN itself disappears;  (b)  lymphocytes may be exposed to IFN produced locally but 
with no access to the circulation and therefore not detected in the peripheral blood; 
and (c) serum IFN levels below those detectable with assays currently available may 
contribute to elevation of 2-5A synthetase. 
Acid-labile leukocyte IFN from SLE patients induced 2-5A synthetase in GM2504 
and MDBK cells in vitro as expected (data not shown). Lymphocytes from eight of 
nine IFN-positive SLE patients had elevated levels of 2-5A synthetase compared with 2144  INTERFERON  IN  SYSTEMIC  LUPUS  ERYTHEMATOSUS 
normal  lymphocytes (Table IV), suggesting  that  SLE patients  do respond to their 
endogenous IFN. In addition, 6 of 10 serum IFN-negative patients had high levels of 
2-5A synthetase, suggesting that  these patients also produced endogenous IFN, but 
that  IFN synthesis was  either transient,  local, or below detectable levels in serum. 
Previous  estimates  of the  number  of  SLE  patients  actually  producing  IFN  are 
therefore probably minimums. 
Discussion 
We  confirmed  that  cells  from  SLE  patients  were  deficient  in  their  ability  to 
synthesize IFN in vitro in response to some inducers. However, cells from SLE patients 
made conventional human alpha, beta, or gamma IFN in response to UC-NDV, poly 
I:C, and PWM, respectively. None of the lymphocyte cultures specifically produced 
acid-labile  alpha  IFN  spontaneously  or  in  response  to  any  of the  inducers  tested 
although all lymphocytes produced acid-labile alpha IFN after stimulation with  C. 
paroum.  While  we  have  not  exhausted  the  list  of potential  IFN  inducers  in  SLE 
patients, these results suggest that peripheral lymphocytes may not be the source of 
the circulating acid-labile alpha IFN in patients with SLE. 
Previous results (8, 9,  14) suggested that measurement of the IFN-induced enzyme 
2-5A synthetase may be a  more sensitive indicator of endogenous IFN  production 
than assay of serum IFN. We found that  14 of 19 patients with SLE (8 of 9 patients 
with circulating IFN, and 6 of 10 patients without detectable serum IFN) had elevated 
levels of2-5A synthetase. Others also found 2-5A synthetase in mononuclear cells from 
patients  with  unspecified  "collagen  diseases"  (9).  These  results  suggest  that  most 
patients with SLE actually produce IFN. However, some patients may produce very 
low levels of IFN, and be recorded as false negatives, or produce IFN transiently or 
cyclically. Alternatively, IFN may be produced in lymphoid organs without enough 
"spillover" into serum to produce detectable IFN levels in all patients. If this is the 
case, local IFN titers could be high enough for potent immunoregulatory effects in 
both serum IFN-positive and serum IFN-negative patients. 
Endogenous  production  of IFN  may  explain  the  abnormally  low  response  of 
lymphocytes from patients with SLE and other immune disorders to mitogens and 
some IFN inducers in vitro. Analogous results were obtained using lymphocytes from 
IFN-treated mice (15).  Our data suggest an inverse correlation between serum IFN 
and the amount of IFN produced in vitro. Patients with circulating IFN presumably 
have more endogenous IFN at that  time than serum IFN-negative patients, so that 
more  pronounced  inhibition  of cellular  responses  by  their  lymphocytes might  be 
expected. Since serum IFN is more frequent in patients with active SLE (1-3), our 
data is consistent with previous results (6) showing a high proportion of nonresponders 
among patients with acute disease and reduced IFN production by cells from patients 
with active SLE compared with those with inactive SLE. Deficient activity of natural 
killer (NK) cells from SLE patients may also be partially due to continuous endoge- 
nous exposure to IFN;  studies with both mice and  humans  have shown  that  long- 
term treatment with IFN can result in depressed NK activity (16). 
Although mononuclear cells from normal individuals appear capable of producing 
an acid-labile alpha IFN in vitro in response to C. parvum (Table IV, and reference 14) 
and after influenza virus challenge (17), this form of alpha IFN is apparently a minor 
component of "conventional" human  alpha IFN preparations. Why this particular PREBLE ET AL.  2145 
alpha IFN is produced out of proportion in patients with autoimmune disease is not 
yet known. There is, however, indirect evidence that IFN may contribute to autoim- 
mune  disease  in  mice  (18,  19). The  immunoregulatory  effects  of "conventional" 
human alpha IFN on normal human lymphocytes are well documented; investigation 
of immunomodulation by acid-labile alpha IFN is currently in progress. 
Summary 
The interferon (IFN)-induced enzyme 2-5A synthetase was elevated in mononuclear 
cells from both serum IFN-positive and -negative systemic lupus erythematosus (SLE) 
patients.  This  suggests that  a  much higher percentage of patients  than  previously 
thought  produce endogenous IFN.  These  results  may partly  explain  findings  that 
mononuclear cells  from  SLE  patients  are  deficient  in  IFN  production  in  vitro  in 
response to certain IFN inducers. Although normal lymphocytes can produce an acid- 
labile alpha IFN after stimulation with C. parvum in vitro, the reason for endogenous 
production of this unusual alpha IFN by SLE patients remains unknown. 
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